Patents by Inventor Parsa Akbari

Parsa Akbari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors
    Patent number: 11957704
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: April 16, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)
    Patent number: 11939635
    Abstract: The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 26, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Manuel Allen Revez Ferreira, Aris Baras
  • Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors
    Patent number: 11759476
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: September 19, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20230172963
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: August 31, 2022
    Publication date: June 8, 2023
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
    Publication number: 20220411870
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: May 19, 2022
    Publication date: December 29, 2022
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina
  • Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors
    Publication number: 20220364099
    Abstract: The present disclosure provides methods of treating a subject having a liver disease or type 2 diabetes, and methods of identifying subjects having an increased risk of developing a liver disease or type 2 diabetes.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 17, 2022
    Inventors: Niek Verweij, Olukayode Sosina, Parsa Akbari, Adam Locke, Aris Baras, Luca Andrea Lotta
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20220313726
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: April 1, 2022
    Publication date: October 6, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20220184114
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 16, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
    Patent number: 11359246
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: June 14, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina
  • Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR)
    Publication number: 20220049308
    Abstract: The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.
    Type: Application
    Filed: August 13, 2021
    Publication date: February 17, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
    Publication number: 20220042101
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 21, 2021
    Publication date: February 10, 2022
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina